THE EUROPEAN CANNABIS OPPORTUNITY
EU MARKET SIZE 2019
There are three main categories of cannabis.
Cannabinoid-based medicine not holding marketing authorisation and therefore sold as an unlicensed medicine that is supplied through health systems and prescribed by a doctor;
Active Pharmaceutical Ingredients (API) to be manipulated and/or compounded by a magistral pharmacy in order to prepare a cannabinoid-based medicine without marketing authorisation (unlicensed).
b) Pharmaceutical Cannabis
Refers to products that have been through clinical trials and licensed as medicine.
CBD and other “over the counter” cannabinoids
CBD is a non-psychoactive chemical entity found in cannabis, that is recently being accepted as safe. CBD is deployed in many over the counter (OTC) products. There are other cannabinoids, terpenes etc. that are considered safe and also deployed into OTC products.
Adult Use/ Recreational
Recreational cannabis is any cannabis used for non-medical purposes, and typically has a higher concentration of THC – the chemical compound that provides the user a “high”. CBD products are used for “wellness purposes” such as sleep and anxiety and do not require a prescription.
With a population of more than double that of the United States and Canada combined, Europe is set to become the world’s largest legal cannabis market and could be worth as much as €123 billion by 2028 according to researchers at Prohibition Partners in a report titled “The European Cannabis Report”.
The UK is AltoVerde’s initial focus as it is the largest one of the largest consumer markets in Europe.
CBD BUSINESS MODEL
EU CBD MARKET SHARE
2021 – €1.25 Billion
2022 – €1.47 Billion
2023 – €1.50 Billion
2024 – €1.55 Billion
2025 – €1.65 Billion
ALTOVERDE's ROUTE TO 1%(CBD) MARKET SHARE in 2025
2021 – 0.07%
2022 – 0.20%
2023 – 0.50%
2024 – 0.70%
2025 – 1.00%
- Generate sufficient initial profit in the first year of operations through the wholesale distribution of AltoVerde’s very attractively priced CBD to support the creation of an extraction facility, laboratories and grow ops in UK or EU.
- To import AltoVerde medicinal cannabis and formulations for patient offerings via Private Clinics.
- Capture a share of the medicinal cannabis market by releasing licensed medicines through a pharmaceutical company joint venture following successful Research & Development and Clinical Trials.
2022 Funding Round tbc
3rd Funding round tbc.